论文部分内容阅读
目的:观察替米沙坦治疗原发性轻、中度高血压病的临床降压效果。方法:112例临床确诊为轻、中度高血压病者,随机分为替米沙坦组(57人)和依那普利组(55人),分别每日早晨服替米沙坦40～80 mg,或依那普利10～20mg,总观察时间为8周。服药后第1,4,8周测定血压,人选时与服药后第8周测定血钾、肝功能、肾功能和血脂。结果:服药第1,4,8周两组血压均较治疗前显著降低(P<0.05),两组疗效差异无统计学意义(P>0.05)。到第8周末,替米沙坦组与依那普利组降压总有效率分别为73.2%与71.7%。与治疗开始前比较,第8周末血钾、肝功能、肾功能无明显改变,替米沙坦组TG较依那普利组显著降低(P<0.05)。结论:替米沙坦对老年原发性轻、中度高血压病患者有良好的降压效果,改善高血压患者的脂质代谢,服用安全。
Objective: To observe the clinical effect of telmisartan in treating primary mild to moderate essential hypertension. Methods: A total of 112 patients with mild or moderate hypertension were randomly divided into telmisartan group (57 persons) and enalapril group (55 persons), and were treated with Telmisartan 40 ~ 80 mg, or enalapril 10 ~ 20mg, the total observation time of 8 weeks. Blood pressure was measured at 1, 4, and 8 weeks after taking the medicine, and serum potassium, liver function, renal function and blood lipid were measured at the 8th week after taking the medicine. Results: The blood pressure of the two groups were significantly lower than those before treatment (P <0.05) at the first, the fourth and the eighth week of medication. There was no significant difference between the two groups (P> 0.05). By the end of the 8th week, the total effective rate of depressurization in telmisartan group and enalapril group was 73.2% and 71.7% respectively. There was no significant change of serum potassium, liver function and renal function at the end of the 8th week when compared with those before the start of treatment. TG in telmisartan group was significantly lower than that in enalapril group (P <0.05). Conclusion: Telmisartan has a good antihypertensive effect on elderly patients with primary mild to moderate essential hypertension and improves lipid metabolism and safety in patients with hypertension.